Although substance use disorders are related to higher mortality risk among patients with attention deficit hyperactivity disorder, less information exists on the impact of ADHD medication on substance...
A recent study compared the effects of extend-release tramadol with clonidine and buprenorphine on withdrawal symptoms and retention among patients with opioid use disorder.
Schizophrenia patients taking antipsychotics face a greater risk of cardiovascular disease. In a recent study, researchers tested the effects of a glucagon-like peptide-1 receptor agonist in schizophrenia...
The findings of a recent study challenge the hypothesis that schizophrenia and other cognitive impairments are associated with GABA deficiency. The study compared the brain chemistry of schizophrenia...
In a new study, researchers aimed to determine the effects of a diabetes drug added to clozapine or olanzapine treatment for schizophrenia. To see the results, including how the drug affected...
Aristada recently received approval from the US Food and Drug Administration for a new and shorter dosing regimen, providing more options to patients and health care providers.
The American Society of Addiction Medicine has issued a consensus document to guide the appropriate use of drug testing in patients with or at risk for addiction.
In a large-scale meta-analysis, researchers analyzed the prevalence and incidence of cardiovascular diseases and cardiovascular-related death in patients with severe mental illness and the general...
In the year following a new psychosis diagnosis, the death rate for young people is 24 times higher than for young people without psychosis, according to a new study published online in Schizophrenia...
